Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow

Executive Summary

Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.

You may also be interested in...



Viatris Pipeline Progress Includes Eylea, Botox Biosimilars

In its first sales and earnings call, Viatris management updated investors on the development of some key complex generics and biosimilars.

Organon Is Ready To Launch And Makes The Case To Investors

Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.

Up To 9,000 Jobs At Risk As Viatris Kicks Off $1bn Restructuring Scheme

With a goal of reducing its cost base by at least $1bn by 2024, Viatris has delivered plans to significantly restructure its global manufacturing network. Up to 20% of Viatris’ 45,000-strong workforce could be impacted by the initiative which will see the firm close, divest or downsize 15 of its manufacturing plants around the globe.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel